Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia.
Anna C McCarterGiusy Della GattaAshley MelnickErin KimCher ShaQing WangJahnavi K NalamoluYiran LiuTheresa M KeeleyRan YanMengxi SunRohan KodguleNicholas KunnathAlberto Ambesi-ImpiombatoRork KuickArvind RaoRussell J H RyanBarbara L KeeLinda C SamuelsonMichael C OstrowskiAdolfo A FerrandoMark Y ChiangPublished in: Blood cancer discovery (2022)
Notch activation is highly prevalent among cancers, in particular T-cell acute lymphoblastic leukemia (T-ALL). However, the use of pan-Notch inhibitors to treat cancers has been hampered by adverse effects, particularly intestinal toxicities. To circumvent this barrier in T-ALL, we aimed to inhibit ETS1, a developmentally important T-cell transcription factor previously shown to co-bind Notch response elements. Using complementary genetic approaches in mouse models, we show that ablation of Ets1 leads to strong Notch-mediated suppressive effects on T-cell development and leukemogenesis, but milder intestinal effects than pan-Notch inhibitors. Mechanistically, genome-wide chromatin profiling studies demonstrate that Ets1 inactivation impairs recruitment of multiple Notch-associated factors and Notch-dependent activation of transcriptional elements controlling major Notch-driven oncogenic effector pathways. These results uncover previously unrecognized hierarchical heterogeneity of Notch-controlled genes and points to Ets1-mediated enucleation of Notch-Rbpj transcriptional complexes as a target for developing specific anti-Notch therapies in T-ALL that circumvent the barriers of pan-Notch inhibition.